Johnny Dy, MD
Cardiovascular Disease · Lenoir, NCNPI 1528021664
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,005 of the $13,853 with a category attached, or 86.7%. 38 manufacturers reported payments, led by Medtronic at 26.9% of the total. Reporting peaked in 2023 at $3,042 and has fallen 67.0% since, to $1,004 in 2025.
Across 606 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Johnson & Johnson$2K
- Novartis$1K
- Amgen$986
- Pfizer$713
- Abbott$703
- plus $5K from 32 others
Across 136 payments — averaging $15,794 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.9M
- Janssen Research & Development, LLC$119K
- Eli Lilly$35K
- Boehringer Ingelheim International GmbH$31K
- Boehringer Ingelheim$28K
- Merck$20K
- plus $59K from 6 others
What the payments were for
- Travel & lodging$1,74013%
- Food & beverage$12,00587%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 56 | $3,728 |
| Johnson & Johnson | 111 | $1,680 |
| Novartis | 61 | $1,067 |
| Amgen | 57 | $986 |
| Pfizer | 45 | $713 |
| Abbott | 25 | $703 |
| Boston Scientific | 22 | $596 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $575 |
| AstraZeneca | 28 | $526 |
| Boehringer Ingelheim | 35 | $481 |
| E.r. Squibb & Sons, L.L.C. | 22 | $361 |
| Novo Nordisk | 23 | $351 |
| Bayer | 17 | $308 |
| Actelion Pharmaceuticals US, Inc. | 3 | $250 |
| Amarin Pharma, Inc. | 12 | $209 |
| Acist Medical Systems, Inc. | 4 | $185 |
| Merck | 10 | $149 |
| Preventric Diagnostics, Inc. | 1 | $118 |
| Vital Connect, Inc | 4 | $103 |
| Abiomed | 1 | $103 |
| Esperion Therapeutics, Inc. | 5 | $97 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $78 |
| Cardinal Health 200 LLC | 2 | $50 |
| Shockwave Medical, Inc | 1 | $42 |
| Irhythm Technologies, Inc. | 3 | $40 |
| GSK | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Bard Peripheral Vascular, Inc. | 1 | $31 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Biotronik Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$1,087
- HawkOne$736
- UPTRAVI$223
- OPSUMIT$223
- WATCHMAN Access System$141
- AVEIR$131
- Repatha$125
- LINQ II$123
- COREVALVE EVOLUT R$119
- BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM$118
- Impella$103
How this compares
$13,853 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 746 | $748,023 |
| BrilintaTicagrelor | 296 | $202,359 |
| JardianceEmpagliflozin | 168 | $172,401 |
| XareltoRivaroxaban | 176 | $164,435 |
| Repatha SureclickEvolocumab | 193 | $160,454 |
| EntrestoSacubitril/Valsartan | 130 | $142,056 |
| MounjaroTirzepatide | 68 | $76,475 |
| OzempicSemaglutide | 21 | $36,746 |
| FarxigaDapagliflozin Propanediol | 14 | $17,322 |
| Praluent PenAlirocumab | 22 | $15,474 |
| Dofetilide | 47 | $13,103 |
| Ranolazine ErRanolazine | 138 | $10,112 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 487 | $10,056 |
| Repatha SyringeEvolocumab | 13 | $9,418 |
| Metoprolol Succinate | 703 | $7,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $713 | $748,023746 claims |
| AstraZenecaBrilinta, Farxiga | $526 | $219,680310 claims |
| Boehringer IngelheimJardiance | $481 | $172,401168 claims |
| Johnson & JohnsonXarelto | $1,680 | $164,435176 claims |
| NovartisEntresto | $1,067 | $142,056130 claims |
| Lilly USA, LLCMounjaro | $20 | $76,47568 claims |
| Novo NordiskOzempic | $351 | $36,74621 claims |
| Esperion Therapeutics, Inc.Nexletol | $97 | $5,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Lenoir
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.